203 related articles for article (PubMed ID: 15453340)
1. [Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].
Ishikawa T; Kakumu S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():331-5. PubMed ID: 15453340
[No Abstract] [Full Text] [Related]
2. [Treatment and selection criteria for chronic hepatitis B].
Gunji T; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():309-12. PubMed ID: 15453336
[No Abstract] [Full Text] [Related]
3. [Lamivudine treatment for hepatitis B].
Lamivudine Clincal Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
[No Abstract] [Full Text] [Related]
4. Changing landscape of antiviral resistance management in chronic hepatitis B.
Nguyen T; Locarnini S; Desmond P
J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
[No Abstract] [Full Text] [Related]
5. [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
Tang Y; Chen G; Zheng R
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):89. PubMed ID: 11983118
[No Abstract] [Full Text] [Related]
6. [Lamivudine treatment consensus from relative experts in 2003].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
[No Abstract] [Full Text] [Related]
7. To stop or not to stop: the quest for long-term viral suppression.
Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2011 Mar; 26(3):420-2. PubMed ID: 21332537
[No Abstract] [Full Text] [Related]
8. [Corticosteroid withdrawal therapy in patients with chronic hepatitis B virus infection].
Akuta N; Kumada H
Nihon Rinsho; 2004 Aug; 62 Suppl 8():345-8. PubMed ID: 15453343
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
10. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
11. [Interferon therapy for chronic hepatitis B].
Kakumu S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():315-20. PubMed ID: 15453337
[No Abstract] [Full Text] [Related]
12. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
[No Abstract] [Full Text] [Related]
13. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
[TBL] [Abstract][Full Text] [Related]
15. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
16. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
17. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients.
Liu F; Wang L; Li XY; Liu YD; Wang JB; Zhang ZH; Wang YZ
J Gastroenterol Hepatol; 2011 Mar; 26(3):456-60. PubMed ID: 21332542
[TBL] [Abstract][Full Text] [Related]
18. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
19. [Early prediction of lamivudine response in e antigen-negative chronic hepatitis B patients].
Li JG; Li JX; Liu MX; Qin HQ; Chai YY; Wang XY; Li SF; Tian SW; Zhao LF; Niu Q; Zhang JQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):745-9. PubMed ID: 19874689
[TBL] [Abstract][Full Text] [Related]
20. [Therapy effects of short-term lamivudine treatment on 22 hepatitis B patients with HBeAg-negative].
Wu TS; Fang P
Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):239. PubMed ID: 12716527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
